

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 4 OCT 03 MATHDI removed from STN  
NEWS 5 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added  
to core patent offices  
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005  
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download  
of CAPLUS documents for use in third-party analysis and  
visualization tools  
NEWS 8 OCT 27 Free KWIC format extended in full-text databases  
NEWS 9 OCT 27 DIOGENES content streamlined  
NEWS 10 OCT 27 EPFULL enhanced with additional content  
NEWS 11 NOV 14 CA/CAPLUS - Expanded coverage of German academic research

NEWS EXPRESS NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005.  
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT  
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:13:26 ON 29 NOV 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:13:54 ON 29 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 NOV 2005 HIGHEST RN 868827-82-1  
DICTIONARY FILE UPDATES: 28 NOV 2005 HIGHEST RN 868827-82-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "M-THPC"/CN 25

E1	1	M-THIOCRESOL/CN
E2	1	M-THIZONE/CN
E3	0 -->	M-THPC/CN
E4	1	M-THYMOL/CN
E5	1	M-THYMOL, 2,2'-(P-METHOXYBENZYLIDENE) DI-/CN
E6	1	M-THYMYL TRICHLOROACETATE/CN
E7	1	M-TMI/CN
E8	1	M-TMXDI/CN
E9	1	M-TMXDU/CN
E10	1	M-TOIN/CN
E11	1	M-TOLIDINE/CN
E12	1	M-TOLIDINE, A,A,A,A',A',A'-HEXAFLUORO-/CN
E13	1	M-TOLIDINE, A,A,A,A',A',A'-HEXAFLUORO-, DITARTRATE/CN
E14	1	M-TOLIDINE, 5-NITRO-/CN
E15	1	M-TOLIDINE, 6,6'-DICHLORO-N,N'-DICINNAMYLDIENE-/CN
E16	1	M-TOLIDINE, COMPD. WITH BUOH/CN
E17	1	M-TOLIDINE, COMPD. WITH FEI2/CN
E18	1	M-TOLIDINE, N-ACETOACETYL-N'-ACETYL-/CN
E19	1	M-TOLIDINE-PYROMELLITIC DIANHYDRIDE COPOLYMER/CN
E20	1	M-TOLIL/CN
E21	1	M-TOLIL, 4,4'-DIETHOXY-/CN
E22	1	M-TOLIL, 4,4'-DIMETHOXY-/CN
E23	1	M-TOLIL, 5,5'-DIETHOXY-4,4'-DIHYDROXY-A,A'-DIMORPHOLINO-/CN
E24	1	M-TOLIL, 5,5'-DIETHOXY-4,4'-DIHYDROXY-A,A'-DIPIPERIDINO-/CN
E25	1	M-TOLIL, 6,6'-DIMETHOXY-/CN

=> E "THPC"/CN 25

E1 1 THP-ADRIAMYCIN HCL/CN  
 E2 1 THP-M/CN  
 E3 1 --> THPC/CN  
 E4 1 THPE/CN  
 E5 1 THPO/CN  
 E6 1 THPO PROTEIN (MOUSE STRAIN FVB/N CLONE MGC:6080 IMAGE:3593885)/CN  
 E7 1 THPOH/CN  
 E8 1 THPOH, POLYMER WITH 1,2-ETHANEDIAMINE/CN  
 E9 1 THPOH, POLYMER WITH 1,3-DICHLORO-2-PROPANOL AND UREA/CN  
 E10 1 THPOH, POLYMER WITH 1,6-HEXANEDIAMINE/CN  
 E11 1 THPOH, POLYMER WITH 3-BROMOPHENOL, 1,2-ETHANEDIAMINE AND  
 FORMALDEHYDE/CN  
 E12 1 THPOH, POLYMER WITH 4-BROMOPHENOL, 1,2-ETHANEDIAMINE,  
 FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E13 1 THPOH, POLYMER WITH 4-BROMOPHENOL, 1,2-ETHANEDIAMINE,  
 FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT),  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM HYDROXIDE AND TETRAKIS(HYDROXYMETHYL)PHOSPHONI/CN  
 E14 1 THPOH, POLYMER WITH AMMONIA/CN  
 E15 1 THPOH, POLYMER WITH AMMONIA, 3-BROMOPHENOL AND FORMALDEHYDE/CN  
 E16 1 THPOH, POLYMER WITH AMMONIA, 3-BROMOPHENOL, FORMALDEHYDE,  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E17 1 THPOH, POLYMER WITH AMMONIA, FORMALDEHYDE AND PHENOL/CN  
 E18 1 THPOH, POLYMER WITH AMMONIA, FORMALDEHYDE, PHENOL,  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E19 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE ((NH4)(OH)),  
 3-BROMOPHENOL, FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E20 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE ((NH4)(OH)),  
 FORMALDEHYDE, PHENOL, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E21 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE, 3-BROMOPHENOL,  
 FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E22 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE, FORMALDEHYDE, PHENOL,  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E23 1 THPOH, POLYMER WITH FORMALDEHYDE, PHENOL AND  
 1,3,5,7-TETRAAZATRICYCLO(3.3.1.1<sup>3,7</sup>)DECANE/CN  
 E24 1 THPOH, POLYMER WITH UREA/CN  
 E25 1 THPOH-NH3/CN

=> S E3

L1 1 THPC/CN

=> DIS L1 1 SQIDE

THE ESTIMATED COST FOR THIS REQUEST IS 6.15 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 124-64-1 REGISTRY

CN Phosphonium, tetrakis(hydroxymethyl)-, chloride (8CI, 9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Tetrakis(hydroxymethyl)phosphonium chloride (6CI)

OTHER NAMES:

CN NSC 30698


CN Pyroset TKC

CN Tetrahydroxymethylphosphonium chloride

CN Tetrakis(hydroxymethyl)phosphochloride

CN Tetramethylolphosphonium chloride

CN **THPC**  
 AR 16980-25-9  
 DR 2245-60-5  
 MF C4 H12 O4 P . Cl  
 CI COM  
 LC STN Files: AGRICOLA, BEILSTEIN\*, BIOSIS, CA, CANCERLIT, CAOLD, CAPLUS,  
 CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, CSNB, DETHERM\*, EMBASE,  
 GMELIN\*, HSDB\*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, NIOSHTIC,  
 PIRA, PROMT, RTECS\*, TOXCENTER, ULIDAT, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 DT.CA Caplus document type: Conference; Journal; Patent; Report  
 RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP  
 (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or  
 reagent); USES (Uses); NORL (No role in record)  
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological  
 study); PREP (Preparation); PRP (Properties); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological  
 study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP  
 (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or  
 reagent); USES (Uses); NORL (No role in record)  
 RLD.NP Roles for non-specific derivatives from non-patents: PREP  
 (Preparation); PROC (Process); USES (Uses)  
 CRN (24655-84-3)



● Cl-

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

695 REFERENCES IN FILE CA (1907 TO DATE)  
 106 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 695 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 50 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> E "THPC"/CN 25

E1 1 THP-ADRIAMYCIN HCL/CN  
 E2 1 THP-M/CN  
 E3 1 --> THPC/CN  
 E4 1 THPE/CN  
 E5 1 THPO/CN  
 E6 1 THPO PROTEIN (MOUSE STRAIN FVB/N CLONE MGC:6080 IMAGE:3593885)/CN  
 E7 1 THPOH/CN  
 E8 1 THPOH, POLYMER WITH 1,2-ETHANEDIAMINE/CN  
 E9 1 THPOH, POLYMER WITH 1,3-DICHLORO-2-PROPANOL AND UREA/CN  
 E10 1 THPOH, POLYMER WITH 1,6-HEXANEDIAMINE/CN  
 E11 1 THPOH, POLYMER WITH 3-BROMOPHENOL, 1,2-ETHANEDIAMINE AND  
 FORMALDEHYDE/CN  
 E12 1 THPOH, POLYMER WITH 4-BROMOPHENOL, 1,2-ETHANEDIAMINE,  
 FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN

E13 1 THPOH, POLYMER WITH 4-BROMOPHENOL, 1,2-ETHANEDIAMINE,  
 FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT),  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM HYDROXIDE AND TETRAKIS(HYDROXYMETHYL)PHOSPHONI/CN  
 E14 1 THPOH, POLYMER WITH AMMONIA/CN  
 E15 1 THPOH, POLYMER WITH AMMONIA, 3-BROMOPHENOL AND FORMALDEHYDE/CN  
 E16 1 THPOH, POLYMER WITH AMMONIA, 3-BROMOPHENOL, FORMALDEHYDE,  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E17 1 THPOH, POLYMER WITH AMMONIA, FORMALDEHYDE AND PHENOL/CN  
 E18 1 THPOH, POLYMER WITH AMMONIA, FORMALDEHYDE, PHENOL,  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E19 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE ((NH4)(OH)),  
 3-BROMOPHENOL, FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E20 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE ((NH4)(OH)),  
 FORMALDEHYDE, PHENOL, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E21 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE, 3-BROMOPHENOL,  
 FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E22 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE, FORMALDEHYDE, PHENOL,  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E23 1 THPOH, POLYMER WITH FORMALDEHYDE, PHENOL AND  
 1,3,5,7-TETRAAZATRICYCLO(3.3.1.1<sup>3,7</sup>)DECANE/CN  
 E24 1 THPOH, POLYMER WITH UREA/CN  
 E25 1 THPOH-NH3/CN

=> E "FOSCAN"/CN 25

E1 1 FOSBROM/CN  
 E2 1 FOSCAMET/CN  
 E3 1 --> FOSCAN/CN  
 E4 1 FOSCARB/CN  
 E5 1 FOSCARBOXIN/CN  
 E6 1 FOSCARNET/CN  
 E7 1 FOSCARNET SODIUM/CN  
 E8 1 FOSCAVIR/CN  
 E9 1 FOSCHLOR/CN  
 E10 1 FOSCHLOR 50/CN  
 E11 1 FOSCHLOR R/CN  
 E12 1 FOSCHLOR R 50/CN  
 E13 1 FOSCO 715/CN  
 E14 1 FOSCOLIC ACID/CN  
 E15 1 FOSDIOL/CN  
 E16 1 FOSDIOL A/CN  
 E17 1 FOSDIOL, POLYMER WITH 1,3-DIISOCYANATOMETHYLBENZENE, GUANIDINE  
 AND POLYMETHYLENEPOLYPHENYLENE ISOCYANATE/CN  
 E18 1 FOSDIOL, POLYMER WITH 1,3-DIISOCYANATOMETHYLBENZENE,  
 POLYMETHYLENEPOLYPHENYLENE ISOCYANATE AND THIOUREA/CN  
 E19 1 FOSDIOL, POLYMER WITH 1,3-DIISOCYANATOMETHYLBENZENE,  
 POLYMETHYLENEPOLYPHENYLENE ISOCYANATE AND UREA/CN  
 E20 1 FOSDIOL, POLYMER WITH ACETAMIDE, 1,3-DIISOCYANATOMETHYLBENZENE  
 AND POLYMETHYLENEPOLYPHENYLENE ISOCYANATE/CN  
 E21 1 FOSDIOL, POLYMER WITH CYANO GUANIDINE,  
 1,3-DIISOCYANATOMETHYLBENZENE AND POLYMETHYLENEPOLYPHENYLENE ISOCYANATE/CN  
 E22 1 FOSDIOL-GUANIDINE-POLYMETHYLENEPOLYPHENYLENE ISOCYANATE-TDI  
 COPOLYMER/CN  
 E23 1 FOSDIOL-POLYMETHYLENEPOLYPHENYLENEISOCYANATE-TDI-THIOUREA  
 COPOLYMER/CN  
 E24 1 FOSDRIN/CN  
 E25 1 FOSECO/CN

=> S E3

L2 1 FOSCAN/CN

=> DIS L2 1 SQIDE

THE ESTIMATED COST FOR THIS REQUEST IS 6.15 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 122341-38-2 REGISTRY

CN Phenol, 3,3',3'',3'''-(7,8-dihydro-21H,23H-porphine-5,10,15,20-tetrayl)tetrakis- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,3',3'',3'''-(7,8-Dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol

CN 5,10,15,20-Tetra(m-hydroxyphenyl)chlorin

CN 5,10,15,20-Tetrakis(m-hydroxyphenyl)chlorin

CN 8-Dihydroporphyrin-5

CN EF 9

CN **Foscan**

CN mTHPC

CN Temoporfin

DR 851449-56-4

MF C44 H32 N4 O4

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CIN, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK\*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS\*, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Other Sources: WHO


DT.CA CAPLUS document type: Conference; Dissertation; Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

282 REFERENCES IN FILE CA (1907 TO DATE)  
20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
282 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

14.17

14.38

FILE 'CAPLUS' ENTERED AT 14:15:49 ON 29 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Nov 2005 VOL 143 ISS 23

FILE LAST UPDATED: 28 Nov 2005 (20051128/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2

L3 282 L2

=> s l3 (L) antibod?

447951 ANTIBOD?

L4 2 L3 (L) ANTIBOD?

=> d ibib 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:747646 CAPLUS

DOCUMENT NUMBER: 135:285081

TITLE: Photodynamic therapy compounds

INVENTOR(S): Vrouenraets, Martinus Bernardus; Stigter, Marijke; Snow, Gordon Brian; Van Dongen, Augustinus Antonius Maria Silverster; Postmus, Pieter Edsge; Visser, Gerardus Wilhelmus Maria; Stewart, Fiona Anne; Oppelaar, Hugo

PATENT ASSIGNEE(S): Neth.

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

-----

----

-----

-----

-----

WO 2001074398      A1      20011011      WO 2000-GB1215      20000330  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,  
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
CA 2376001      AA      20011011      CA 2000-2376001      20000330  
PRIORITY APPLN. INFO.:      WO 2000-GB1215      W 20000330  
OTHER SOURCE(S):      MARPAT 135:285081  
REFERENCE COUNT:      10      THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4      ANSWER 2 OF 2      CAPLUS      COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER:      1999:241777      CAPLUS  
DOCUMENT NUMBER:      131:41580  
TITLE:      Development of meta-tetrahydroxyphenylchlorin-  
monoclonal antibody conjugates for photoimmunotherapy  
AUTHOR(S):      Vrouwenraets, Maarten B.; Visser, Gerard W. M.;  
Stewart, Fiona A.; Stigter, Marijke; Oppelaar, Hugo;  
Postmus, Pieter E.; Snow, Gordon B.; van Dongen, Guus  
A. M. S.  
CORPORATE SOURCE:      Departments of Otolaryngology/Head and Neck Surgery,  
Free University Hospital, Amsterdam, 1081 HV, Neth.  
SOURCE:      Cancer Research (1999), 59(7), 1505-1513  
CODEN: CNREA8; ISSN: 0008-5472  
PUBLISHER:      AACR Subscription Office  
DOCUMENT TYPE:      Journal  
LANGUAGE:      English  
REFERENCE COUNT:      51      THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s antibod  
L5      22 ANTIBOD

=> s antibod?  
L6      447951 ANTIBOD?

=> s 16 and 13  
L7      13 L6 AND L3

=> s 17 not py>1999  
6119825 PY>1999  
L8      2 L7 NOT PY>1999

=> d ibib 1-2

L8      ANSWER 1 OF 2      CAPLUS      COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER:      1999:241777      CAPLUS  
DOCUMENT NUMBER:      131:41580  
TITLE:      Development of meta-tetrahydroxyphenylchlorin-  
monoclonal **antibody** conjugates for  
photoimmunotherapy  
AUTHOR(S):      Vrouwenraets, Maarten B.; Visser, Gerard W. M.;  
Stewart, Fiona A.; Stigter, Marijke; Oppelaar, Hugo;  
Postmus, Pieter E.; Snow, Gordon B.; van Dongen, Guus  
A. M. S.  
CORPORATE SOURCE:      Departments of Otolaryngology/Head and Neck Surgery,  
Free University Hospital, Amsterdam, 1081 HV, Neth.



SOURCE: Cancer Research (1999), 59(7), 1505-1513  
CODEN: CNREA8; ISSN: 0008-5472  
PUBLISHER: AACR Subscription Office  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1998:370899 CAPLUS  
DOCUMENT NUMBER: 129:133195  
TITLE: Selective accumulation of meso-  
tetra(hydroxyphenyl)chlorin in steroid-synthesizing  
cells of the rat adrenal gland  
AUTHOR(S): Colombo-Benkmann, Mario; Muhm, Markus; Gahlen,  
Johannes; Vry, Magnus-Sebastian; Deubzer, Hedwig;  
Hollooschi, Andreas; Hafner, Matthias; Heym, Christine;  
Senninger, Norbert  
CORPORATE SOURCE: Dept. of Surgery, Univ. of Heidelberg, Heidelberg,  
69120, Germany  
SOURCE: Proceedings of SPIE-The International Society for  
Optical Engineering (1998), 3260(Optical  
Investigations of Cells in Vitro and in Vivo), 136-140  
CODEN: PSISDG; ISSN: 0277-786X  
PUBLISHER: SPIE-The International Society for Optical Engineering  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs 2

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1998:370899 CAPLUS  
DOCUMENT NUMBER: 129:133195  
TITLE: Selective accumulation of meso-  
tetra(hydroxyphenyl)chlorin in steroid-synthesizing  
cells of the rat adrenal gland  
AUTHOR(S): Colombo-Benkmann, Mario; Muhm, Markus; Gahlen,  
Johannes; Vry, Magnus-Sebastian; Deubzer, Hedwig;  
Hollooschi, Andreas; Hafner, Matthias; Heym, Christine;  
Senninger, Norbert  
CORPORATE SOURCE: Dept. of Surgery, Univ. of Heidelberg, Heidelberg,  
69120, Germany  
SOURCE: Proceedings of SPIE-The International Society for  
Optical Engineering (1998), 3260(Optical  
Investigations of Cells in Vitro and in Vivo), 136-140  
CODEN: PSISDG; ISSN: 0277-786X  
PUBLISHER: SPIE-The International Society for Optical Engineering  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Rat adrenal glands fluoresce intensely after systemic application of  
meso-tetra(hydroxyphenyl)chlorin (m THPC). We investigated which parts of  
the adrenal gland accumulate mTHPC. Furthermore we examined the time course  
of adrenal mTHPC-accumulation. Ten male Wistar rats each were given 0.5  
or 0.7 mg mTHPC kg-1 i.v. Each two animals were perfused with normal  
saline and Zamboni fixative 6, 12, 24, 48 and 72 h after  
photosensitization. Untreated animals served as controls. Fluorescence  
was quantified on 20 µm frozen sections with CCD-camera and appropriate  
software. Immunohistochem. identified specific cell types with  
**antibodies** to steroid-synthesizing enzymes. The cortex exhibited  
an intense fluorescence, with weaker fluorescence of corticocytes in the

zona glomerulosa compared to the other zones. Besides intensely fluorescing singly lying scattered cells, the medulla showed a faint mTHPC-induced fluorescence. Immunohistochem. revealed that intramedullary cells with intense fluorescence were corticocytes, showing a pos. reaction to the 21- $\beta$ -hydroxylase **antibody**. Peak accumulation of mTHPC was always observed after 24 h. Our results indicate for the first time that only steroid synthesizing cells of the adrenal gland exhibit an intense photosensitizer-induced fluorescence. Thus mTHPC-application is an uncomplicated method to identify steroid-synthesizing cells, possibly also in other organs.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file pctfull  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
16.41	30.79

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.73	-0.73

CA SUBSCRIBER PRICE.

FILE 'PCTFULL' ENTERED AT 14:18:03 ON 29 NOV 2005  
COPYRIGHT (C) 2005 Univentio

FILE LAST UPDATED: 22 NOV 2005 <20051122/UP>  
MOST RECENT UPDATE WEEK: 200546 <200546/EW>  
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> KWIC format free of charge - SEE NEWS >>>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE  
[http://www.stn-international.de/stndatabases/details/ipc\\_reform.html](http://www.stn-international.de/stndatabases/details/ipc_reform.html) <

=> s ?thpc  
L9 94 ?THPC

=> s antibod?  
L10 82883 ANTIBOD?

=> s ?porphyrin or ?chlorin  
3943 ?PORPHYRIN  
511 ?CHLORIN  
L11 4116 ?PORPHYRIN OR ?CHLORIN

=> s l11/ab  
LEFT TRUNCATION IGNORED FOR '?CHLORIN/A' FOR FILE 'PCTFULL'  
LEFT TRUNCATION IGNORED FOR '?CHLORIN' FOR FILE 'PCTFULL'  
170 PORPHYRIN/AB  
18 CHLORIN/AB  
L12 182 (?PORPHYRIN/AB OR ?CHLORIN/AB)

Left truncation is not valid in the specified search field in the specified file. The term has been searched without left truncation. Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID' would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you used a truncation symbol after a punctuation mark, the system may interpret the truncation symbol as being at the beginning of a term. Implied proximity is used in search fields indexed as single words,

for example, the Basic Index.

```
=> s (porphyrin or chlorin)/ab
      170 PORPHYRIN/AB
      81 PORPHYRINS/AB
      229 PORPHYRIN/AB
          ((PORPHYRIN OR PORPHYRINS)/AB)
      18 CHLORIN/AB
      15 CHLORINS/AB
      30 CHLORIN/AB
          ((CHLORIN OR CHLORINS)/AB)
L13      242 (PORPHYRIN OR CHLORIN)/AB
```

```
=> s l9 and l13
L14      11 L9 AND L13
```

```
=> s l14 and l10
L15      4 L14 AND L10
```

```
=> s l15 and conjugat?
      70662 CONJUGAT?
L16      4 L15 AND CONJUGAT?
```

```
=> s l16 not py>1999
      614766 PY>1999
L17      1 L16 NOT PY>1999
```

=> d ibib

```
L17      ANSWER 1 OF 1      PCTFULL      COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER:      1998025648 PCTFULL      ED 20020514
TITLE (ENGLISH):      USE OF A TEXAPHYRIN IN OCULAR DIAGNOSIS AND THERAPY
TITLE (FRENCH):      UTILISATION DE TEXAPHYRINE DANS LA PREPARATION D'UN
                        MEDICAMENT EMPLOYE EN DIAGNOSTIC ET THERAPIE OCULAIRES
INVENTOR(S):      BLUMENKRANZ, Mark, S.;
                        WOODBURN, Kathryn, W.;
                        MILLER, Richard, A.;
                        YOUNG, Stuart, W.
PATENT ASSIGNEE(S):      PHARMACYCLICS, INC.;
                        BLUMENKRANZ, Mark, S.;
                        WOODBURN, Kathryn, W.;
                        MILLER, Richard, A.;
                        YOUNG, Stuart, W.
LANGUAGE OF PUBL.:      English
DOCUMENT TYPE:      Patent
PATENT INFORMATION:
                        NUMBER      KIND      DATE
                        -----
DESIGNATED STATES      WO 9825648      A2 19980618
W:      AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
      ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK
      LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD
      SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM
      KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
      CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF
      CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.:      WO 1997-US22661      A 19971211
PRIORITY INFO.:      US 1996-08/763,451      19961211
```

=> d his

(FILE 'HOME' ENTERED AT 14:13:26 ON 29 NOV 2005)

FILE 'REGISTRY' ENTERED AT 14:13:54 ON 29 NOV 2005

```
      E "M-THPC"/CN 25
      E "THPC"/CN 25
L1      1 S E3
      E "THPC"/CN 25
      E "FOSCAN"/CN 25
L2      1 S E3
```

FILE 'CAPLUS' ENTERED AT 14:15:49 ON 29 NOV 2005

```
L3      282 S L2
L4      2 S L3 (L) ANTIBOD?
L5      22 S ANTIBOD
L6      447951 S ANTIBOD?
L7      13 S L6 AND L3
L8      2 S L7 NOT PY>1999
```

FILE 'PCTFULL' ENTERED AT 14:18:03 ON 29 NOV 2005

```
L9      94 S ?THPC
L10     82883 S ANTIBOD?
L11     4116 S ?PORPHYRIN OR ?CHLORIN
L12     182 S L11/AB
L13     242 S (PORPHYRIN OR CHLORIN)/AB
L14     11 S L9 AND L13
L15     4 S L14 AND L10
L16     4 S L15 AND CONJUGAT?
L17     1 S L16 NOT PY>1999
```

=> s l11 and l10

```
L18     1960 L11 AND L10
```

=> s conjugat? and l18

```
      70662 CONJUGAT?
L19     1515 CONJUGAT? AND L18
```

=> s conjugat? (P) l6

```
      70662 CONJUGAT?
      82883 ANTIBOD?
L20     47135 CONJUGAT? (P) L6
```

=> s l20 and l11

```
L21     1491 L20 AND L11
```

=> s l11/clm

LEFT TRUNCATION IGNORED FOR '?CHLORIN/C' FOR FILE 'PCTFULL'

LEFT TRUNCATION IGNORED FOR '?CHLORIN' FOR FILE 'PCTFULL'

```
      607 PORPHYRIN/CLM
      127 CHLORIN/CLM
L22     665 (?PORPHYRIN/CLM OR ?CHLORIN/CLM)
```

Left truncation is not valid in the specified search field in the specified file. The term has been searched without left truncation. Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID' would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you used a truncation symbol after a punctuation mark, the system may interpret the truncation symbol as being at the beginning of a term. Implied proximity is used in search fields indexed as single words, for example, the Basic Index.

=> d his

(FILE 'HOME' ENTERED AT 14:13:26 ON 29 NOV 2005)

FILE 'REGISTRY' ENTERED AT 14:13:54 ON 29 NOV 2005

E "M-THPC"/CN 25  
E "THPC"/CN 25  
L1 1 S E3  
E "THPC"/CN 25  
E "FOSCAN"/CN 25  
L2 1 S E3

FILE 'CAPLUS' ENTERED AT 14:15:49 ON 29 NOV 2005

L3 282 S L2  
L4 2 S L3 (L) ANTIBOD?  
L5 22 S ANTIBOD  
L6 447951 S ANTIBOD?  
L7 13 S L6 AND L3  
L8 2 S L7 NOT PY>1999

FILE 'PCTFULL' ENTERED AT 14:18:03 ON 29 NOV 2005

L9 94 S ?THPC  
L10 82883 S ANTIBOD?  
L11 4116 S ?PORPHYRIN OR ?CHLORIN  
L12 182 S L11/AB  
L13 242 S (PORPHYRIN OR CHLORIN)/AB  
L14 11 S L9 AND L13  
L15 4 S L14 AND L10  
L16 4 S L15 AND CONJUGAT?  
L17 1 S L16 NOT PY>1999  
L18 1960 S L11 AND L10  
L19 1515 S CONJUGAT? AND L18  
L20 47135 S CONJUGAT? (P) L6  
L21 1491 S L20 AND L11  
L22 665 S L11/CLM

=> s l21 not py>1999  
614766 PY>1999  
L23 321 L21 NOT PY>1999

=> s conjugat? (P) l10  
70662 CONJUGAT?  
L24 47135 CONJUGAT? (P) L10

=> s l11 (P) conjugat?  
70662 CONJUGAT?  
L25 1919 L11 (P) CONJUGAT?

=> s l25 and l24  
L26 1403 L25 AND L24

=> s l26 and l9  
L27 20 L26 AND L9

=> s l27 not py>1999  
614766 PY>1999  
L28 2 L27 NOT PY>1999

=> d ibib 1-2

L28 ANSWER 1 OF 2 PCTFULL COPYRIGHT 2005 Univentio on STN  
ACCESSION NUMBER: 1998052609 PCTFULL ED 20020514  
TITLE (ENGLISH): SONODYNAMIC THERAPY USING AN ULTRASOUND SENSITIZER  
COMPOUND  
TITLE (FRENCH): THERAPIE SONODYNAMIQUE METTANT EN OEUVRE UN COMPOSE

INVENTOR(S):	SENSIBILISANT ULTRASONORE ALFHEIM, Jan, Alan; HENRICHS, Paul, Mark; HOHENSCHUH, Eric, Paul; JOHANNESSEN, Edvin, Wilhelm; SANDERSON, William, Anthony; SNOW, Robert, Allen		
PATENT ASSIGNEE(S):	NYCOMED IMAGING AS; ALFHEIM, Jan, Alan; HENRICHS, Paul, Mark; HOHENSCHUH, Eric, Paul; JOHANNESSEN, Edvin, Wilhelm; SANDERSON, William, Anthony; SNOW, Robert, Allen		
LANGUAGE OF PUBL.:	English		
DOCUMENT TYPE:	Patent		
PATENT INFORMATION:			
	NUMBER	KIND	DATE
	-----		
	WO 9852609	A1	19981126
DESIGNATED STATES			
W:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-GB1444	A	19980519
PRIORITY INFO.:	GB 1997-9710049.9		19970519
L28 ANSWER 2 OF 2	PCTFULL COPYRIGHT 2005 Univentio on STN		
ACCESSION NUMBER:	1998025648 PCTFULL ED 20020514		
TITLE (ENGLISH):	USE OF A TEXAPHYRIN IN OCULAR DIAGNOSIS AND THERAPY		
TITLE (FRENCH):	UTILISATION DE TEXAPHYRINE DANS LA PREPARATION D'UN MEDICAMENT EMPLOYE EN DIAGNOSTIC ET THERAPIE OCULAIRES		
INVENTOR(S):	BLUMENKRANZ, Mark, S.; WOODBURN, Kathryn, W.; MILLER, Richard, A.; YOUNG, Stuart, W.		
PATENT ASSIGNEE(S):	PHARMACYCLICS, INC.; BLUMENKRANZ, Mark, S.; WOODBURN, Kathryn, W.; MILLER, Richard, A.; YOUNG, Stuart, W.		
LANGUAGE OF PUBL.:	English		
DOCUMENT TYPE:	Patent		
PATENT INFORMATION:			
	NUMBER	KIND	DATE
	-----		
	WO 9825648	A2	19980618
DESIGNATED STATES			
W:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1997-US22661	A	19971211
PRIORITY INFO.:	US 1996-08/763,451		19961211

=> d kwic 2

L28 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2005 Univentio on STN

DETD 0 Photodynamic therapy of conditions in the eye characterized by neovascularization has been attempted using conventional **porphyrin** derivatives such as **hematoporphyrin** derivative (**dihematoporphyrin** ether), **PHOTOFRIN** and **porfimer** sodium, and tin ethyl etiopurpurin. Problems have been encountered in this context due to interference from eye pigments, as described in U.S. Patent 5,576,013 to Williams, et al. for example. In addition, **phthalocyanine** and **benzoporphyrin** derivatives have been used in photodynamic treatment. PCT publication WO 95/24930 and Miller et al., (Archives of Ophthalmology, June, 1995) relate to treatment of eye conditions characterized by unwanted neovasculature comprising administering a green **porphyrin** to the neovasculature and irradiating the neovasculature with light having a wavelength of 550-695 nm. U.S. Patents 5,166,197 and 5,484,778 relate. . . .

sodium (PHOTOFRIN and, requiring light of 630 nm and causing cutaneous photosensitivity that may last for up to 6 weeks), and **benzoporphyrin** derivative (BPD verteporfin, causing cutaneous photosensitivity of a few days). Lin et al. (IOVS 34:1303 Abstract 2953, 1993) relate to the photodynamic occlusion of choroidal vessels using **benzoporphyrin** derivative BPD-MA. Baumal et al. (Invest. Ophthalmol. Vis. Sci. 37/3:S122 (abstract) 1996) relates to PDT of experimental choroidal neovascularization with. . . .

an advantage in the ocular methods of use provided herein, providing for rapid infusion as a bolus as compared to BPD, **mTHPC**, or **SnET2** which require solubilizing vehicles such as lipid environments, for example; and further obviating the need for a lipophilic. . . .

#### ABBREVIATIONS

ARMD	Age related macular degeneration
7	
BPD	- <b>Benzoporphyrin</b> derivative
IN	- Inferonasal
IT	- Inferotemporal
CNV (M)	Choroidal neovascularization (membrane)
FWHM	- full width half maximum
HDL	- high-density lipoproteins
ICG	indocyanine green
LDL	Low density lipoprotein
Lu(III)T2BET	- lutetium texaphyrin, T2BET
<b>mTHPC</b>	<b>Tetra(m-hydroxyphenyl)chlorin</b>
NZW	New Zealand White
OD	Right eye
OS	Left eye
PDT	Photodynamic therapy

SN	Superonasal
SnET2 -	Tin etiopurpurin
ST	Superotemporal
TGF-b -	Transforming growth factor-b
Txp	Texaphyrin
0	VEGF. . .

In an embodiment of the present invention, texaphyrins are further coupled to site-directing molecules to form **conjugates** for targeted in vivo delivery. "Site-directing" means having specificity for targeted sites. "Specificity for targeted sites"

means that upon contacting the texaphyrin-**conjugate** with the targeted site, for example, 5 under physiological conditions of ionic strength, temperature, pH and the like, specific binding will occur. The interaction may occur due to specific electrostatic,

hydrophobic, entropic or other interaction of certain residues of the **conjugate** with

specific residues of the target to form a stable complex under conditions effective to

promote the interaction. A site-directing. . . limited to:

lipoproteins including low density lipoprotein; cholesterol; polyamides including peptides having affinity for an ocular

receptor; proteins such as **antibodies** or an immunologically active fragment thereof;

15

oligonucleotides complementary to an ocular DNA or RNA; histamine; hormone

mimics such as morphine; a. . .

derivatives of amino acids

like; derivatives thereof; and texaphyrin metal complexes. The term "appended to the

texaphyrin complex-site directing molecule **conjugate**" means

that the catalytic groups

are attached either directly to the texaphyrin metal complex or to the texaphyrin

complex via a linker or couple of variable length, or are attached to the ligand portion o

0 a texaphyrin complex-ligand **conjugate** either with or without a linker or couple of variable length

the lipoprotein phase of the blood, LDL is expected to more efficiently deliver texaphyrin to the target tissue. A texaphyrin-LDL

**conjugate** is selective for

neovascularization since leakage of the **conjugate** is expected to occur only in

neovasculature due to the large size of the **conjugate**. LDL can be isolated and purified

0 according to the procedure of Haul et al., (J. Clin. Invest., 34:1345, 1995)

In most preferred embodiments, **conjugates** and appended groups are covalently

bonded to the texaphyrin via a carbon-carbon, carbon-nitrogen, carbon-sulfur, or a

carbon-oxygen bond, more preferably a. . .



Treatment of carboxylated texaphyrins with thionyl chloride or p-nitrophenol acetate would generate activated acyl species suitable for attachment to monoclonal

5 **antibodies** or other biomolecules of interest. Standard in situ coupling methods (e.g., 1,1'-carbonyldiimidazole) could be used to effect the **conjugation**